124 related articles for article (PubMed ID: 6783296)
1. Phase I and pharmacological studies of pentamethylmelamine administered by 24-hour intravenous infusion.
Casper ES; Gralla RJ; Lynch GR; Jones BR; Woodcock TM; Gordon C; Kelsen DP; Young CW
Cancer Res; 1981 Apr; 41(4):1402-6. PubMed ID: 6783296
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of pentamethylmelamine in patients with previously treated malignancies.
Van Echo DA; Chiuten DF; Whitacre M; Aisner J; Lichtenfeld JL; Wiernik PH
Cancer Treat Rep; 1980; 64(12):1335-9. PubMed ID: 6781747
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of pentamethylmelamine: a clinical and pharmacologic study.
Ihde DC; Dutcher JS; Young RC; Cordes RS; Barlock AL; Hubbard SM; Jones RB; Boyd MR
Cancer Treat Rep; 1981; 65(9-10):755-62. PubMed ID: 6791819
[TBL] [Abstract][Full Text] [Related]
4. Early clinical trial of a 1-day intermittent schedule for pentamethylmelamine.
Eagan RT; Creagan ET; Rubin J; O'Connell MJ; Kovach JS
Cancer Treat Rep; 1980; 64(8-9):993-5. PubMed ID: 6778613
[TBL] [Abstract][Full Text] [Related]
5. Phase I and clinical pharmacological evaluation of a parenteral hexamethylmelamine formulation.
Ames MM; Richardson RL; Kovach JS; Moertel CG; O'Connell MJ
Cancer Res; 1990 Jan; 50(1):206-10. PubMed ID: 2104537
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).
Judson IR; Calvert AH; Rutty CJ; Abel G; Gumbrell LA; Graham MA; Evans BD; Wilman DE; Ashley SE; Cairnduff F
Cancer Res; 1989 Oct; 49(19):5475-9. PubMed ID: 2670205
[TBL] [Abstract][Full Text] [Related]
8. Disposition and metabolism of pentamethylmelamine and hexamethylmelamine in rabbits and humans.
Ames MM; Powis G; Kovach JS; Eagan RT
Cancer Res; 1979 Dec; 39(12):5016-21. PubMed ID: 115586
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of pentamethylmelamine.
Ajani JA; Cabanillas FF; Bodey GP
Cancer Treat Rep; 1982 May; 66(5):1227-8. PubMed ID: 6805950
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors.
Ramnath N; Schwartz GN; Smith P; Bong D; Kanter P; Berdzik J; Creaven PJ
Cancer Chemother Pharmacol; 2003 Mar; 51(3):227-30. PubMed ID: 12655441
[TBL] [Abstract][Full Text] [Related]
11. Pentamethylmelamine (PMM): Phase I clinical and pharmacokinetic studies.
Muindi JR; Newell DR; Smith IE; Harrap KR
Br J Cancer; 1983 Jan; 47(1):27-33. PubMed ID: 6401427
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of pentamethylmelamine.
Goldberg RS; Griffin JP; McSherry JW; Krakoff IH
Cancer Treat Rep; 1980; 64(12):1319-22. PubMed ID: 6781746
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
14. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
[TBL] [Abstract][Full Text] [Related]
15. A sensitive and specific assay for pentamethylmelamine in plasma: applicability to clinical studies.
Dutcher JS; Jones RB; Boyd MR
Cancer Treat Rep; 1980 Jan; 64(1):99-104. PubMed ID: 6769585
[TBL] [Abstract][Full Text] [Related]
16. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
17. Phase I evaluation and pharmacokinetics of aziridinylbenzoquinone using a weekly intravenous schedule.
Schilcher RB; Young JD; Leichman LP; Haas CD; Baker LH
Cancer Res; 1983 Aug; 43(8):3907-11. PubMed ID: 6683127
[TBL] [Abstract][Full Text] [Related]
18. Pentamethylmelamine: review of an aqueous analog of hexamethylmelamine.
Foster BJ; Clagett-Carr K; Hoth D; Leyland-Jones B
Cancer Treat Rep; 1986 Mar; 70(3):383-9. PubMed ID: 3082512
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
